← All trials
NCT01265810
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2011
- Primary completion
- Aug 31, 2015
- Completion date
- Oct 31, 2015
- First posted
- Dec 23, 2010
- Last posted
- Nov 13, 2017
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Impaqtt FoundationLead sponsor
- CB Boers ORGCollaborator
- CB Boers ORGOverall official - principal investigator
- Jazz PharmaceuticalsCollaborator
- Leiden UniversityCollaborator
- Leiden UniversityStudy chair
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- PfizerCollaborator
- Memorial Sloan-Kettering Cancer CenterOfficial
- CB Boers ORGOfficial
- NovartisCollaborator
- Leiden UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.